

Remington's Pharmaceutical Sciences

EDITED BY THE EDITORIAL BOARD OF THE AMERICAN PHARMACEUTICAL ASSOCIATION

Eighteenth Edition

Entered according to Act of Congress, in the year 1885 by Joseph P Remington,
in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by Joseph P Remington Estate

Copyright 1948, 1951, by The Philadelphia College of Pharmacy and Science

Copyright © 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, by The Philadelphia College of
Pharmacy and Science

All Rights Reserved

Library of Congress Catalog Card No. 60-53334

ISBN 0-912734-04-3

*The use of structural formulas from USAN and the USP Dictionary of Drug Names is by
permission of The USP Convention. The Convention is not responsible for any inaccuracy
contained herein.*

*NOTICE—This text is not intended to represent, nor shall it be interpreted to be, the equivalent
of or a substitute for the official United States Pharmacopeia (USP) and/or the National
Formulary (NF). In the event of any difference or discrepancy between the current official
USP or NF standards of strength, quality, purity, packaging and labeling for drugs and
representations of them herein, the context and effect of the official compendia shall
prevail.*

Printed in the United States of America by the Mack Printing Company, Easton, Pennsylvania

Table of Contents

| | | | |
|---|-----|---|------|
| Part 1 Orientation | | 44 Cholinomimetic Drugs | 889 |
| 1 Scope | 3 | 45 Adrenergic and Adrenergic Neuron Blocking Drugs | 898 |
| 2 Evolution of Pharmacy | 8 | 46 Antimuscarinic and Antispasmodic Drugs | 907 |
| 3 Ethics | 20 | 47 Skeletal Muscle Relaxants | 916 |
| 4 The Practice of Community Pharmacy | 28 | 48 Diuretic Drugs | 929 |
| 5 Opportunities for Pharmacists in the Pharmaceuti- cal Industry | 33 | 49 Uterine and Antimigraine Drugs | 943 |
| 6 Pharmacists in Government | 38 | 50 Hormones | 948 |
| 7 Drug Information | 49 | 51 Vitamins and Other Nutrients | 1002 |
| 8 Research | 60 | 52 Enzymes | 1035 |
| Part 2 Pharmaceutics | | 53 General Anesthetics | 1039 |
| 9 Metrology and Calculation | 69 | 54 Local Anesthetics | 1048 |
| 10 Statistics | 104 | 55 Sedatives and Hypnotics | 1057 |
| 11 Computer Science | 138 | 56 Antiepileptics | 1072 |
| 12 Calculus | 145 | 57 Psychopharmacologic Agents | 1082 |
| 13 Molecular Structure, Properties and States of Matter | 158 | 58 Analgesics and Antipyretics | 1097 |
| 14 Complex Formation | 182 | 59 Histamine and Antihistamines | 1123 |
| 15 Thermodynamics | 197 | 60 Central Nervous System Stimulants | 1132 |
| 16 Solutions and Phase Equilibria | 207 | 61 Antineoplastic and Immunosuppressive Drugs ... | 1138 |
| 17 Ionic Solutions and Electrolytic Equilibria | 228 | 62 Antimicrobial Drugs | 1163 |
| 18 Reaction Kinetics | 247 | 63 Parasitocides | 1242 |
| 19 Disperse Systems | 257 | 64 Pesticides | 1249 |
| 20 Rheology | 310 | 65 Diagnostic Drugs | 1272 |
| Part 3 Pharmaceutical Chemistry | | 66 Pharmaceutical Necessities | 1286 |
| 21 Inorganic Pharmaceutical Chemistry | 329 | 67 Adverse Drug Reactions | 1330 |
| 22 Organic Pharmaceutical Chemistry | 356 | 68 Pharmacogenetics | 1344 |
| 23 Natural Products | 380 | 69 Pharmacological Aspects of Drug Abuse | 1349 |
| 24 Drug Nomenclature—United States Adopted Names | 412 | 70 Introduction of New Drugs | 1365 |
| 25 Structure-Activity Relationship and Drug Design | 422 | Part 7 Biological Products | |
| Part 4 Testing and Analysis | | 71 Principles of Immunology | 1379 |
| 26 Analysis of Medicinals | 435 | 72 Immunizing Agents and Diagnostic Skin Antigens | 1389 |
| 27 Biological Testing | 484 | 73 Allergenic Extracts | 1405 |
| 28 Clinical Analysis | 495 | 74 Biotechnology and Drugs | 1416 |
| 29 Chromatography | 529 | Part 8 Pharmaceutical Preparations and Their Manufacture | |
| 30 Instrumental Methods of Analysis | 555 | 75 Preformulation | 1435 |
| 31 Dissolution | 589 | 76 Bioavailability and Bioequivalency Testing | 1451 |
| Part 5 Radioisotopes in Pharmacy and Medicine | | 77 Separation | 1459 |
| 32 Fundamentals of Radioisotopes | 605 | 78 Sterilization | 1470 |
| 33 Medical Applications of Radioisotopes | 624 | 79 Tonicity, Osmoticity, Osmolality and Osmolarity . | 1481 |
| Part 6 Pharmaceutical and Medicinal Agents | | 80 Plastic Packaging Materials | 1499 |
| 34 Diseases: Manifestations and Patho- physiology | 655 | 81 Stability of Pharmaceutical Products | 1504 |
| 35 Drug Absorption, Action and Disposition | 697 | 82 Quality Assurance and Control | 1513 |
| 36 Basic Pharmacokinetics | 725 | 83 Solutions, Emulsions, Suspensions and Extractives | 1519 |
| 37 Clinical Pharmacokinetics | 746 | 84 Parenteral Preparations | 1545 |
| 38 Topical Drugs | 757 | 85 Intravenous Admixtures | 1570 |
| 39 Gastrointestinal Drugs | 774 | 86 Ophthalmic Preparations | 1581 |
| 40 Blood, Fluids, Electrolytes and Hematologic Drugs | 800 | 87 Medicated Applications | 1596 |
| 41 Cardiovascular Drugs | 831 | 88 Powders | 1615 |
| 42 Respiratory Drugs | 860 | 89 Oral Solid Dosage Forms | 1633 |
| 43 Sympathomimetic Drugs | 870 | 90 Coating of Pharmaceutical Dosage Forms | 1666 |
| | | 91 Sustained-Release Drug Delivery Systems | 1676 |
| | | 92 Aerosols | 1694 |
| | | Part 9 Pharmaceutical Practice | |
| | | 93 Ambulatory Patient Care | 1715 |
| | | 94 Institutional Patient Care | 1737 |
| | | 95 Long-Term Care Facilities | 1758 |
| | | 96 The Pharmacist and Public Health | 1773 |

CHAPTER 89

Oral Solid Dosage Forms

Edward Rudnic, PhD

Director, Formulation Development
Schering-Plough Research
Miami, FL 33169

Joseph D Schwartz, PhD

Tice Professor of Pharmaceutics
Philadelphia College of Pharmacy and Science
Philadelphia, PA 19104

Drug substances most frequently are administered orally by means of solid dosage forms such as tablets and capsules. Large-scale production methods used for their preparation, as described later in the chapter, require the presence of other materials in addition to the active ingredients. Additives also may be included in the formulations to enhance the physical appearance, improve stability and aid in disintegration after administration. These supposedly inert ingredients, as well as the production methods employed, have been shown in some cases to influence the release of the drug substances.¹ Therefore care must be taken in the selection and evaluation of additives and preparation methods to ensure that the physiological availability and therapeutic efficacy of the active ingredient will not be diminished.

In a limited number of cases it has been shown that the drug substance's solubility and other physical characteristics have influenced its physiological availability from a solid dosage form. These characteristics include its particle size, whether it is amorphous or crystalline, whether it is solvated or nonsolvated and its polymorphic form. After clinically effective formulations are obtained, variations among dosage units of a given batch, as well as batch-to-batch differences, are reduced to a minimum through proper in-process controls and good manufacturing practices. The recognition of the importance of validation both for equipment and processes has greatly enhanced assurance in the reproducibility of formulations. It is in these areas that significant progress has been made with the realization that large-scale production of a satisfactory tablet or capsule depends not only on the availability of a clinically effective formulation



Fig 89-1. Tablet press operators checking batch record in conformance with Current Good Manufacturing Practices (courtesy, Lilly).

but also on the raw materials, facilities, personnel, validated processes and equipment, packaging and the controls used during and after preparation (Fig 89-1).

Tablets

Tablets may be defined as solid pharmaceutical dosage forms containing drug substances with or without suitable diluents and prepared either by compression or molding methods. They have been in widespread use since the latter part of the 19th century and their popularity continues. The term *compressed tablet* is believed to have been used first by John Wyeth and Brother of Philadelphia. During this same period, molded tablets were introduced to be used as "hypodermic" tablets for the extemporaneous preparation of solutions for injection. Tablets remain popular as a dosage form because of the advantages afforded both to the manufacturer (eg, simplicity and economy of preparation, stability and convenience in packaging, shipping and dispensing) and the patient (eg, accuracy of dosage, compactness, portability, blandness of taste and ease of administration).

Although the basic mechanical approach for their manufacture has remained the same, tablet technology has undergone great improvement. Efforts are being made continually to understand more clearly the physical characteristics of tablet compression and the factors affecting the availability

of the drug substance from the dosage form after oral administration. Compression equipment continues to improve both as to production speed and the uniformity of tablets compressed. Recent advances in tablet technology have been reviewed.⁸⁻¹³

Although tablets frequently are more discoid in shape, they also may be round, oval, oblong, cylindrical or triangular. They may differ greatly in size and weight depending on the amount of drug substance present and the intended method of administration. They are divided into two general classes, whether they are made by compression or molding. Compressed tablets usually are prepared by large-scale production methods while molded tablets generally involve small-scale operations. The various tablet types and abbreviations used in referring to them are listed below.

Compressed Tablets (CT)

These tablets are formed by compression and contain no special coating. They are made from powdered, crystalline or granular materials, alone or in combination with binders, disintegrants, lubricants, diluents and in many cases, colorants.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.